Here, we have demonstrated that the characteristic oncogene CRKL is the downstream effector of Hh‐GLI2 pathway, providing CRKL as a putative drug target for Hh‐related NSCLC. The gene discussed is GLI2; the disease is non-small cell lung carcinoma.